...Sanifit, which spun out of the University of the Balearic Islands, is developing lead program SNF472...
...develop SNF472 further in a specific indication. Perelló said the biotech believes it can commercialize SNF472...
...Alta's Guy Paul Nohra and Columbus' Damià Tormo joined Sanifit's board. Paul Bonanos, Associate Editor SNF472, SNF-472 Laboratoris...

...Laboratoris Sanifit S.L. (Palma de Mallorca, Spain) said IV SNF472 met the primary endpoint of improving...
...the Bates-Jensen Wound Assessment Tool (BWAT) in a single-arm Phase II trial to treat calciphylaxis. SNF472...
...Status: Phase II data Milestone: Additional Phase II data (mid-2018); start Phase III (2018) Jennie Walters SNF472, SNF-472 Laboratoris...

...S.L. 's SNF472 is the only other program in clinical development to treat vascular calcification. SNF472...
...ESRD) patients on dialysis. At the American Society of Nephrology meeting in 2015, Sanifit reported SNF472...
...patients; whereas SNF472 requires an IV infusion. Sanifit CEO Joan Perelló told BioCentury that developing SNF472...

...Sanifit began an open-label, international Phase II trial to evaluate SNF472 given over 3 months in...
...skin and fatty tissue. Laboratoris Sanifit S.L. , Palma de Mallorca, Spain Product: SNF472 , SNF-472...

...in Roche (SIX:ROG; OTCQX:RHHBY) veteran Pieter Joubert in 2011 to spearhead development of lead asset SNF-472...
...Joubert was global head of clinical pharmacology at Roche. Mulder also noted Sanifit significantly de-risked SNF-472...
...the compound's "straight-forward development path" with well-defined endpoints. The cash will finance proof-of-concept studies for SNF-472...

...Baxter Healthcare also participated alongside existing investors La Caixa; HealthEquity; and undisclosed angel investors. Sanifit's SNF-472...